Vista Investment Partners II LLC Grows Holdings in Cencora, Inc. (NYSE:COR)

Vista Investment Partners II LLC boosted its stake in Cencora, Inc. (NYSE:COR - Free Report) by 14.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,017 shares of the company's stock after purchasing an additional 1,246 shares during the quarter. Cencora comprises approximately 1.5% of Vista Investment Partners II LLC's portfolio, making the stock its 22nd biggest holding. Vista Investment Partners II LLC's holdings in Cencora were worth $2,786,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Price T Rowe Associates Inc. MD raised its stake in Cencora by 0.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,859,452 shares of the company's stock valued at $1,990,542,000 after purchasing an additional 78,066 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Cencora by 62.3% during the fourth quarter. Bank of America Corp DE now owns 5,193,807 shares of the company's stock worth $1,166,944,000 after acquiring an additional 1,994,256 shares in the last quarter. Boston Partners raised its stake in shares of Cencora by 2.6% during the fourth quarter. Boston Partners now owns 5,007,100 shares of the company's stock worth $1,128,058,000 after acquiring an additional 125,611 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Cencora by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company's stock worth $969,471,000 after acquiring an additional 130,213 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of Cencora by 20.4% during the fourth quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock worth $728,757,000 after acquiring an additional 550,246 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on COR. UBS Group lifted their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Citigroup lifted their price target on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Robert W. Baird lifted their price target on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Bank of America lifted their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Finally, Morgan Stanley set a $288.00 price target on shares of Cencora in a research note on Tuesday, April 15th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, Cencora currently has a consensus rating of "Moderate Buy" and an average price target of $306.91.

Cencora Trading Up 1.1%

Shares of Cencora stock traded up $3.13 on Friday, hitting $299.71. The stock had a trading volume of 2,156,014 shares, compared to its average volume of 1,504,613. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. Cencora, Inc. has a one year low of $218.65 and a one year high of $309.35. The stock has a market cap of $58.09 billion, a price-to-earnings ratio of 34.77, a PEG ratio of 1.48 and a beta of 0.58. The stock's 50-day simple moving average is $289.95 and its two-hundred day simple moving average is $265.45.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. The business had revenue of $75.50 billion for the quarter, compared to analysts' expectations of $75.41 billion. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.80 earnings per share. As a group, sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.73%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's dividend payout ratio (DPR) is currently 25.52%.

Insider Activity at Cencora

In other news, CEO Robert P. Mauch sold 4,969 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the sale, the chief executive officer now owns 47,582 shares in the company, valued at approximately $13,766,900.06. The trade was a 9.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of the company's stock in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the completion of the sale, the chairman now directly owns 315,913 shares in the company, valued at $89,027,442.53. This represents a 4.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,127 shares of company stock worth $9,812,296 over the last quarter. Corporate insiders own 10.80% of the company's stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.